Uncover key drivers, emerging technologies, and competitive movements shaping the workstation graphics processing unit (gpu) market from 2026–2035 with trusted insights from The Business Research Company
How is the Tumor Blood Testing Market size predicted to change over the forecast window of 2026–2035?
The tumor blood testing market size has shown substantial growth over recent years. This market is expected to expand from $5.98 billion in 2025 to $6.78 billion in 2026, achieving a compound annual growth rate (CAGR) of 13.3%. The growth observed in the past can be linked to an increase in cancer prevalence, inherent limitations of tissue biopsy, ongoing advancements in genomic testing, consistent oncology research funding, and a rising demand for non-invasive diagnostics.
The tumor blood testing market size is projected to experience substantial expansion over the coming years. This market is set to reach $11.13 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 13.2%. This anticipated growth during the forecast period stems from factors such as the implementation of early cancer screening programs, advancements in AI-enabled genomic analysis, the rise of personalized medicine, the broader use of companion diagnostics, and increased adoption in clinical trials. Key developments shaping the market within this period encompass the widespread adoption of liquid biopsy, multi-cancer early detection initiatives, sophisticated minimal residual disease monitoring, the proliferation of personalized oncology testing, and the evolution of high-sensitivity biomarker detection.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28343&type=smp
Which Drivers Are Contributing To The Expansion Of The Tumor Blood Testing Market?
The rising incidence of cancer is anticipated to propel the expansion of the tumor blood testing market in the foreseeable future. An aging demographic and exposure to various risk factors, including inadequate nutrition, tobacco use, and environmental contaminants, are leading to a greater occurrence of cancer, thereby boosting the need for early detection solutions. Tumor blood testing offers a non-invasive way to identify cancer through biomarkers in the bloodstream prior to the onset of noticeable symptoms. Such testing facilitates prompt diagnosis, allows for early intervention, enhances patient results, and permits continuous tracking of disease advancement and treatment efficacy. For example, in May 2024, data from the National Cancer Institute, a US-based government agency, indicated that as of January 2022, approximately 18.1 million cancer survivors resided in the United States, with forecasts predicting this number to climb to 26 million by 2040. Consequently, the expanding occurrence of cancer is a key factor propelling the development of the tumor blood testing market.
What Segment Categories Are Covered In The Tumor Blood Testing Market?
The tumor blood testing market covered in this report is segmented –
1) By Test Type: Circulating Tumor Cells (CTC) Tests, Circulating Tumor DNA (CtDNA) Tests, Exosome-Based Tests, Other Test Types
2) By Technology: Polymerase Chain Reaction (PCR)-Based Testing, Next-Generation Sequencing, Immunoassays
3) By Cancer Type: Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Melanoma
4) By Application: Early Cancer Screening, Therapy Selection, Treatment Monitoring, Recurrence Monitoring
5) By End User: Hospitals, Diagnostic Laboratories, Research Institutes, Other End-Users
Subsegments:
1) By Circulating Tumor Cells Tests: Isolation Of Tumor Cells, Enumeration Of Tumor Cells, Characterization Of Tumor Cells
2) By Circulating Tumor DNA Tests: Mutation Detection Of Tumor DNA, Methylation Analysis Of Tumor DNA, Copy Number Variation Analysis Of Tumor DNA, Fragmentation Analysis Of Tumor DNA
3) By Exosome-Based Tests: Protein Profiling Of Exosomes, RNA Profiling Of Exosomes, Lipid Profiling Of Exosomes, Surface Marker Analysis Of Exosomes
4) By Other Tests: Circulating RNA Tests, Tumor Educated Platelet Tests, Protein Biomarker Panels, Multiomics Blood Tests, Immuno Oncology Biomarker Tests
What Trends Are Projected To Support The Growth Of The Tumor Blood Testing Market?
Leading companies in the tumor blood testing sector are concentrating on developing innovative technologies, particularly non-invasive liquid biopsy techniques, to enable earlier detection of cancer, monitor the effectiveness of treatments, and more efficiently assess disease progression. These non-invasive liquid biopsy technologies are diagnostic examinations that identify and analyze cancer-related biomarkers from bodily fluids, presenting a safer and more convenient option than traditional tissue biopsies. For example, in February 2024, Delfi Diagnostics, a US-based biotechnology company, in collaboration with Immunocore Holdings plc, a UK-based biotechnology company, introduced the DELFI-Tumor Fraction (DELFI-TF) assay, which is a blood test for monitoring cancer. This assay functions by analyzing cell-free DNA (cfDNA) fragments within the bloodstream to evaluate tumor burden and how well a patient is responding to treatment. This particular fragmentome-based liquid biopsy provides a non-invasive, cost-efficient alternative to conventional approaches, requiring minimal plasma and delivering results within two weeks.
Which Leading Companies Dominate The Tumor Blood Testing Market Share?
Major companies operating in the tumor blood testing market are Bio-Techne Corporation, Roche Holding AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Natera Inc., Myriad Genetics Inc., Neogenomics Laboratories Inc., Guardant Health Inc., Foundation Medicine Inc., Adaptive Biotechnologies Corporation, Freenome Holdings Inc., Grail Inc., Personal Genome Diagnostics Inc., Exosome Diagnostics Inc., Agena Bioscience Inc., Menarini Silicon Biosystems S.p.A.
Access The Complete Report For Deeper Market Insights:
https://www.thebusinessresearchcompany.com/report/tumor-blood-testing-global-market-report
Which Region Is Anticipated To See The Fastest Growth In The Tumor Blood Testing Market?
North America was the largest region in the tumor blood testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tumor blood testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Tumor Blood Testing Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=28343&type=smp
Browse Through More Reports Similar to the Global Tumor Blood Testing Market 2026, By The Business Research Company
Hemato Oncology Testing Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/hemato-oncology-testing-global-market-report
Cancer Diagnostics Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report
Blood Screening Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/blood-screening-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company